W

hen Biogen received regulatory approval last month to sell the Spinraza rare disease drug, the company surprised Wall Street by setting a price that few expected — $750,000 for the first year of treatment and $375,000 each year thereafter. At the time, at least one analyst suggested the price tag amounted to “sticker shock” that may cheer investors, but also invite criticism amid growing outrage over drug pricing.

Already, the scrutiny has begun.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy